Effects of casoxin 4 on morphine inhibition of small animal intestinal contractility and gut transit in the mouse

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 23-31

  Patten, Glen S ^a   Head, Richard J ^a   Abeywardena, Mahinda Y ^a  

^a CSIRO   (Australia)

Author keywords

opioid receptor antagonist; Lactoferroxin A; Opioid agonists

Indexed keywords

CASOXIN 4; DELTA OPIATE RECEPTOR; DYNORPHIN A; KAPPA OPIATE RECEPTOR; LACTOFERROXIN A; METENKEPHALIN; MORPHICEPTIN; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; FUNCTIONAL ELECTRICAL STIMULATION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRANSIT; GUINEA PIG; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CONTRACTION; MALE; MILK; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; RAT; SPECIES COMPARISON; STOMACH EMPTYING;

EID: 79952945100     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S16161     Document Type: Article

References (45)

1. Schulz R, Wuster M, Herz A. Centrally and peripherally mediated inhibition of intestinal motility by opioids. Naunyn-Schmiedebergs Arch Pharmacol. 1979;308:255-260.
2. Galligan JJ, Burks TF. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Ex Ther. 1983; 226:57-61.
3. Smith CFC, Waldron C, Brook NA. Opioid receptors in the mouse ileum. Arch Int Pharmacodyn. 1988;291:122-131.
4. Porreca F, Mosberg HI, Hurst R, et al. Roles for mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther. 1984;230:341-348.
5. Coupar IM, de Luca A. Opiate and opiate antidiarrhoeal drug action on isolated rat intestine. J Auton Pharmacol. 1994;14:69-78.
6. Broccardo M, Improta G, Tabacco A. Central effects of SNC 80, a selective and systemically active d-opioid receptor agonists, on gastrointestinal propulsion in the mouse. Eur J Pharmacol. 1998;342:247-251.
7. Patten GS, Head RJ, Abeywardena MY, et al. An apparatus to assay opioid activity in the infused lumen of the intact isolated guinea pig ileum. J Pharmacol Toxicol Methods. 2001;45:39-46.
8. Milne RJ, Coddington JM, Gamble GD. Quaterary naloxone blocks morphine analgesia in spinal but not intact rats. Neurosci Lett. 1990; 114:259-264.
9. Zimmerman DM, Gidda JS, Cantrell BE, et al. Discovery of a potent peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994;37:2262-2265.
10. Neary P, Delaney CP. Alvimopan. Expert Opin Investig Drugs. 2005; 14:479-488.
11. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373:1198-1206.
12. The role of opioid receptor antagonists in the treatment of opioidinduced constipation: a review. Adv Ther. 2010;27:714-730.
13. McNicol ED, Boyce D, Schumann, et al. Mu-opioid antagonists for opioid- induced bowel dysfunction. Cochrane Database Syst Rev. 2008;2: CD006332.
14. Medical News Today. Phase 2 data from oral NKTR-118 presented at American College of Gastroenterology in San Diego. 2009. Available from: http://www.medicalnewstoday.com/articles/168923.php. Accessed Dec 10 2010.
15. Clinical Trials. Theravance begins proof of concept TD-1211 phase 2 trial. 2010. Available from: http://clinicaltrials.pharmaceuticalbusiness-review.com/news/theravance_begins_proof_of_concept_td1211_phase_2_trial_100415. Accessed Dec 10 2010.
16. Clinical Trials. A study of RDC-1036 (ALKS 37) in adults with opioidinduced constipation (OIC). 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01100151. Accessed Dec 10 2010.
17. The Medical News. Adolor initiates ADL5945 phase 2 proof-ofconcept study for patients with OIC. 2010. Available from: http://www.news-medical.net/news/20101019/Adolor-initiates-ADL5945-Phase-2-proof-of-concept-study-for-patients-with-OIC.aspx. Accessed Dec 10 2010.
18. Bajka BH, Clarke JM, Topping DL, et al. Butyrylated starch increase large bowel butyrate levels and lowers colonic smooth muscle contractility in rats. Nutr Res. 2010;30:427-434.
19. Patten GS, Bird AR, Topping DL, et al. Dietary fish oil alters the sensitivity of guinea pig ileum to electrically driven contractions and 8-iso-PGE2. Nutr Res. 2002;22:1413-1426.
20. Patten GS, Bird AR, Topping DL, et al. Effects of convenience rice congee supplemented diets on guinea pig whole animal and gut growth, caecal digesta SCFA and in vitro ileal contractility. Asia Pacific J Clin Nutr. 2004;13:92-100.
21. Shinohara H, Williams C, Koldovsky O. The use of Poly R-478 as a marker to determine gastric emptying and intestinal propulsive motility in suckling rats. Physiol Res. 1995;44:281-286.
22. Stahl GE, Fayer JC, Ling SC, et al. Comparison of nonabsorbable markers Poly R-478 and [14C]PEG-4,000 for use in developmental absorption studies. J Pediatr Gastroenterol Nutr. 1991;12: 485-493.
23. Patten GS, Augustin MA, Sanguansri L, et al. Site specific delivery of microencapsulated fish oil to the gastrointestinal tract of the rat. Dig Dis Sci. 2009;54:511-521.
24. Chiba H, Yoshikawa M. Biological functional peptides from food proteins: new opioid peptides from milk proteins. In: Feeney RE, Whitaker JR, editors. Protein Tailoring for Food and Medical Uses. New York, NY: Marcel Dekker; 1986:123-152.
25. Yoshikawa M, Tani F, Ashikaga T, et al. Purification and characterization of an opioid antagonist from a peptic digest of bovine κ-casein. Agric Biol Chem. 1986;50:2951-2953.
26. Yoshikawa M, Tani F, Chiba H. Structure-activity relationship of opioid antagonist peptides derived from milk proteins. In: Shiba T, Sakakibara S, editors. Peptide Chemistry. Osaka, Japan: Protein Research Foundation; 1987:473-476.
27. Tani K, Kunihiko I, Chiba H, et al. Isolation and characterization of opioid antagonist peptides derived from human lactoferrin. Agric Biol Chem. 1990;54:1803-1810.
28. Buento L, Fioramonti J. Action of opiates on gastrointestinal function. In: Grundy D, Read NW, editors. Bailliere's Clin Gastroenterol International Practice and Research. Volume 2. London, UK: Bailliere Tindall; 1988:123-139.
29. Kokoska ER, Smith GS, Deshpande Y, et al. Indomethicin increases susceptibility to injury in human gastric cells independent of PG synthesis inhibition. Am J Physiol Gastrointest Liver Physiol. 1998;38: G620-G628.
30. Schaumann W. The paralysing action of morphine on the guinea-pig ileum. Br J Pharmacol Chemother. 1955;10:456-461.
31. Paton WDM, Visi ES. The inhibitory action of noradrenaline and adrenaline on acetylcholine output by guinea-pig ileum longitudinal muscle strip. Br J Pharmacol. 1969;35:10-28.
32. Cucumel K, Bagnol D, Moinier D, et al. The rat dermorphin-like immunoreactivity is supported by an aminopeptidase resistant peptide. J Neuroimmunol. 1998;81:211-224.
33. Galligan JJ, Mosberg HI, Hurst R, et al. Cerebral delta opioid receptors mediate analgesia but not the intestinal motility effects of intracerebroventricularly administered opioids. J Pharmacol Exp Ther. 1984;229:641-648.
34. Coupar IM. The peristaltic reflex in the rat ileum: evidence for functional μ- and d-opiate receptors. J Pharm Pharmacol. 1995;47: 643-646.
35. Davis TP, Gillespie TJ, Shook J, et al. Changes in opioid receptor selectivity following processing of peptide E: effect on gut motility. Gastroenterology. 1991;100:1603-1615.
36. Ghayur MN, Gilani AH, Houghton PJ. Species differences in the gut stimulatory effects of radish seeds. J Pharm Pharmacol. 2005;57: 1493-1501.
37. Matthies H, Stark H, Hartrodt B. Derivatives of β-casomorphins with high analgesic potency. Peptides. 1984;5:463-470.
38. Yuan CS, Foss JF, O'Conner M, et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain. 1999;83:631-635.
39. Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001;182(Suppl):19S-26S.
40. Yuan CS, Foss JF, O'Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000;67:398-404.
41. Yuan CS, Foss JF. Methylnaltrexone: investigation of clinical applications. Drug Dev Res. 2000;50:133-141.
42. Greenwood-van Meerveld B, Standifer KM. Methylnaltrexone in the treatment of opioid-induced constipation. Clin Expt Gastroenterol. 2008;1:49-58.
43. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009; 13:56-64.
44. Thomas JB, Mascarella SW, Burgess JP, et al. N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methylbenzo[g]isoquinolines are opioid receptor pure antagonists. Bioorg Med Chem Lett. 1998;8: 3149-3152.
45. Thomas JB, Zheng X, Mascarella SW, et al. N-substituted 9ß-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists. J Med Chem. 1998;41:4143-4149.